GenSciences

GeneScience Pharmaceuticals Co., Ltd. (GenSci) is a biopharmaceutical company established in 1996, operating as a key subsidiary of the publicly traded Changchun High-Tech Industries Group. The company was co-founded by Dr. Lei Jin, who currently serves as CEO and Chief Scientist. Dr. Jin earned a Ph.D. from the University of California and gained experience at the U.S. biomedical firm Genentech before returning to China in 1995 to establish the company with funding from Changchun High and New Tech. Headquartered in the Changchun High-Tech Development Zone, a national hub for biomedicine, GenSci leverages genetic engineering and recombinant technology to develop and manufacture its products.

GenSci's business model is centered on the research, development, manufacturing, and commercialization of genetically engineered pharmaceuticals. The company primarily serves markets in pediatric health, women's health, and wound healing, with strategic expansion into endocrinology, immunology, and oncology. A significant milestone was the 1998 launch of Jintropin®, the first recombinant human growth hormone (rhGH) in China. This product line has since expanded, making GenSci a global provider in the rhGH market. Another key achievement includes the 2014 release of Jintrolong®, recognized as the world's first long-acting growth hormone injection. The company's R&D efforts are substantial, with an investment of over RMB 2.4 billion in 2023, representing 16.48% of its revenue. GenSci has also established a global innovation hub in Shanghai to accelerate its R&D pipeline.

The company's product portfolio is diverse, featuring a range of biologics and innovative biogenerics. Core products include the Jintropin® and Jintrolong® brands of somatropin for treating growth hormone deficiencies in both pediatric and adult patients. Other notable products are Genfulin® (Molgramostim Gel) for wound healing and tissue repair, and Jinfollin®, a Follitropin injection for women's health. These products address conditions such as pediatric growth failure, Turner syndrome, and adult growth hormone deficiency. GenSci markets its products through a combination of direct sales and partnerships, with a growing global presence in regions like Southeast Asia and Central America. Keywords: GeneScience Pharmaceuticals, GenSci, Dr. Lei Jin, recombinant human growth hormone, rhGH, Jintropin, Jintrolong, somatropin, biopharmaceutical, genetic engineering, pediatric health, women's health, endocrinology, molgramostim, follitropin, Changchun High-Tech, biologics, biogenerics, pharmaceutical manufacturing, clinical development, life sciences